Voyager Therapeutics
Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy
Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development